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Abstract
We have earlier shown that clumping factor A (ClfA), a fibrinogen binding surface protein of Staphylococcus aureus,i sa n
important virulence factor in septic arthritis. When two amino acids in the ClfA molecule, P336 and Y338, were changed to
serine and alanine, respectively, the fibrinogen binding property was lost. ClfAP336Y338 mutants have been constructed in
two virulent S. aureus strains Newman and LS-1. The aim of this study was to analyze if these two amino acids which are vital
for the fibrinogen binding of ClfA are of importance for the ability of S. aureus to generate disease. Septic arthritis or sepsis
were induced in mice by intravenous inoculation of bacteria. The clfAP336Y338 mutant induced significantly less arthritis than
the wild type strain, both with respect to severity and frequency. The mutant infected mice developed also a much milder
systemic inflammation, measured as lower mortality, weight loss, bacterial growth in kidneys and lower IL-6 levels. The data
were verified with a second mutant where clfAP336 and Y338 were changed to alanine and serine respectively. When sepsis
was induced by a larger bacterial inoculum, the clfAP336Y338 mutants induced significantly less septic death. Importantly,
immunization with the recombinant A domain of ClfAP336SY338A mutant but not with recombinant ClfA, protected against
septic death. Our data strongly suggest that the fibrinogen binding activity of ClfA is crucial for the ability of S. aureus to
provoke disease manifestations, and that the vaccine potential of recombinant ClfA is improved by removing its ability to
bind fibrinogen.
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Introduction
Clumping factor A (ClfA) is a surface located protein of
Staphylococcus aureus. ClfA contains a 519 amino acid N-terminal A
domain, which comprises three separately folded subdomains N1,
N2 and N3. The A domain is followed by a serine-aspartate
dipeptide repeat region and a cell wall- and membrane-spanning
region, which contains the LPDTG-motif for sortase-promoted
anchoring to the cell wall. ClfA is present in practically all S. aureus
strains [1]. It binds to the C-terminus of the c-chain of fibrinogen,
and is thereby able to induce clumping of bacteria in fibrinogen
solution [2,3].
Expression of ClfA on S. aureus hampers phagocytosis by both
macrophages and neutrophils [4,5]. In neutrophils this is due to
both a fibrinogen-dependent mechanism and to a fibrinogen-
independent mechanism. In contrast, platelets are activated by
bacteria expressing ClfA through its interaction with GPIIb/IIIa
leading to aggregation. This is most efficiently executed when
fibrinogen is present, but there is also a fibrinogen-independent
pathway for platelet activation [6,7].
We have earlier shown that ClfA is a virulence factor
for induction of septic arthritis in mice [8]. Also, elimination of
ClfA together with another fibrinogen binding protein ClfB
protected against systemic inflammation at the early stages of
infection [9].
It is not known how expression of ClfA contributes to the
development of arthritis and sepsis. Especially, the role of the
interaction between ClfA and host fibrinogen in the pathogenesis
of severe staphylococcal infections is presently unclear. In this
study the role of fibrinogen binding of ClfA in promoting the
virulence of S. aureus was investigated in depth.
A fibrinogen binding-deficient mutant of ClfA was con-
structed by exchanging amino acids P336 and Y338 for serine
and aspartate, respectively. This mutant protein did not pro-
mote detectable bacterial adherence to immobilized fibrinogen
or bacterial clumping in a solution of fibrinogen [6]. The
conformation of single ClfA P336S and ClfAY338A mutants
were unaltered according to far-UV circular dichroism spectros-
copy [10]. The wild-type chromosomal clfA genes of
strains Newman and LS1 were exchanged for the clfA
P336SY338A mutant and the strains were tested in well established
infection models of murine septic arthritis and sepsis [11,12]. In
addition a deletion mutant lacking ClfA expression was compared
to the wildtype and non-fibrinogen binding ClfA expressing
mutant. Our data strongly suggest that interaction between ClfA
and fibrinogen is crucial for infection morbidity and mortality, and
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2206points out a possibility to create a more efficient approach to
vaccination.
Results
Exchange of two amino acids necessary for ClfA binding
to fibrinogen hampers development of septic arthritis
and sepsis
Two amino acids (P336 and Y338) that are known to be
required for fibrinogen binding by ClfA were altered by allelic
exchange to create mutants of strains Newman and LS1 that
expressed a non-fibrinogen-binding ClfA protein on the cell
surface. The level of expression and integrity of the protein was
measured by Western blotting.
The ability of Newman wild-type and Newman clfA P336S
Y338A( clfAPYI) to provoke septic arthritis was investigated. Septic
arthritis was induced by intravenous inoculation of 3.5610
6 to
5.0610
6 colony-forming units (cfu) and 3.2610
6 to 6.0610
6 cfu of
Newman wild-type and the clfAPYI mutant, respectively. The
development of arthritis was studied clinically for 7 days. The
clfAPYI mutant provoked significantly less severe arthritis than the
wild-type strain over the entire experimental period (P.0.001,
Fig. 1 A). The frequency of arthritis was lower for Newman
clfAPYI at all time points (Fig. S1).
We reasoned that the new amino acid composition in the
ClfAPYI molecule accidentally fits for interaction with a host anti-
bacterial defence which could be a possible explanation for our
data. To check for this possibility, a new construct was made
where different amino acids were substituted for P336 and Y338
(clfA P336AY 338S:clfAPYII). Mice that were inoculated with
3.9610
6 cfu of Newman clfAPYII developed arthritis to the same
low extent as the clfAPYI mutant (Fig. 1 A), and with a similar
frequency (Fig. S1). This outcome suggests strongly that the loss of
fibrinogen binding is responsible for the reduced level of arthritis.
It is possible that ClfA is involved in the development of arthritis
by mechanisms that do not involve fibrinogen binding. A clfA
deletion mutant lacking the ClfA protein was compared to
mutants expressing the modified non-fibrinogen binding ClfA
protein. However, mice that were infected with 4.3610
6 to
4.8610
6 cfu of clfA null mutant developed arthritis in a manner
not different from the clfAPYI and clfAPYII mutant infected mice
(Fig. 1 A). The frequency of arthritis was also indistinguishable
(Fig. S1).
Infected joints were also investigated histologically. The
synovitis in Newman clfAPYI-infected mice was significantly
milder than in wild-type infected mice in both experiment 1 and
2( P=0.02 and 0.001, respectively, Table 1). Bone destruction, a
major cause of sequels in human septic arthritis, was almost absent
in the Newman clfAPYI-infected samples (Experiment 2,
P=0.001, Table 1). The synovitis and bone destruction induced
by the Newman clfA null mutant were also less pronounced
compared to mice infected with Newman wild-type (P=0.003 and
0.006, respectively, Table 1), but somewhat more severe than in
the Newman clfAPYI group, although not significantly so.
Next, the metabolic consequences of the clfA mutations for the
infectious process were analysed. Mice infected with the Newman
wild-type strain lost up to about 30% of their body weight during
the experimental period. Mice that were infected with the
fibrinogen binding-deficient mutants Newman clfAPYI and New-
man clfAPYII lost hardly any weight at all (P.0.0001 versus wild-
type). In contrast, the Newman clfA null mutant had an
intermediate effect on the weight loss, causing significantly less
than the wild-type strain, but significantly more than the clfAPYI
and clfAPYII mutant strains (P # 0.02 in most cases, Fig. 1 B).
The serum levels of IL-6, a measure of systemic inflammatory
response, were analyzed at day 7–8 of infection. The pattern of IL-
6 expression was similar to weight changes. Newman wild-type
evoked high levels of serum IL-6 (4.8 (2.8, 5.7) ng/ml), the
Newman clfAPYI mutant evoked considerably lower IL-6 (0.2
(0.07, 2.4) ng/ml, P,0.0001) while the Newman clfA null mutant
gave rise to an intermediate response (2.5 (1.3, 3.2) ng/ml) with
significant differences to both the wild-type and clfAPYI mutant
group (P=0.009 and P=0.008, respectively) (median, interquar-
tile range).
The growth of bacteria in kidneys was significantly greater in
Newman wild-type-infected mice, compared to both of the
Newman clfAPY mutants and the Newman clfA null mutant
(P,0.0001, P=0.011, and P=0.005, respectively; Figure 2). The
Newman clfA null mutant-infected mice had significantly more
Figure 1. The fibrinogen binding site of ClfA mediates
development of septic arthritis and loss of weight. Severity of
arthritis (A), measured as arthritic index, and weight loss (B) in mice
inoculated with S. aureus strain Newman, and clfAPYI, clfAPYII, and clfA
null mutants. 3.2610
6–6.0610
6 cfu of S. aureus strains were inoculated.
Data are represented as medians (squares or center lines), interquartile
ranges (boxes), and 80% central ranges (whiskers). Data are from three
experiments are pooled. NNewman=27–30, NclfAPYI=30, NclfAPYII=10, and
NclfA=16–20.
doi:10.1371/journal.pone.0002206.g001
ClfA, Fibrinogen and Virulence
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(P=0.0005, Fig. 2).
Total IgG in sera was measured in mice on day 7–8 of infection.
There was a significantly lower increase of IgG levels in both the
Newman clfAPYI- and Newman clfA null mutant-infected groups
as compared to mice infected with the wild-type strain (3.1 (1.2,
4.9); 2.3 (1.0, 2.6); and 6.4 (5.0, 11.0), respectively (median,
interquartile range); P # 0.0003). There were no significant
differences between the two mutant groups.
The mortality was 17% in the Newman wild type-infected mice,
0% in the Newman clfAPYI and clfAPYII mutant groups and 30%
in the Newman clfA null mutant group. There were significant
differences in mortality between the wild-type and the clfAPYI
groups, and between the clfAPYI and clfA null mutant groups
(P,0.05 and P,0.01, respectively).
We conclude that direct and indirect signs of systemic
inflammation are lower in mice infected with S.aureus expressing
ClfA that is deficient in fibrinogen binding. Unexpectedly, the
strain which lacked ClfA expression altogether induced more
systemic inflammation than a ClfAPY mutant-expressing strain.
There could be activities mediated by ClfA that do not involve
fibrinogen binding but which are protective to the host with
respect to systemic inflammation.
Sepsis was induced in mice by increasing the inoculation dose of
S. aureus. Mice were infected with 5.2610
7 cfu of Newman wild
type, 5.1610
7 cfu of the Newman clfAPYI mutant and 3.3610
7 cfu
of the Newman clfA null mutant. Within 5 days all wild-type
infected mice were dead, but only one clfAPYI mutant mouse out
of ten were dead after 10 days of infection (P,0.0001, Fig. 3).
Mice infected with the clfA null mutant also survived a significantly
shorter time than the clfAPYI mutant- infected mice (P,0.0001,
Fig. 3). In this experiment the mice challenged with the clfA null
mutant developed significantly more arthritis than the clfAPYI
mutant group, while at the same time they lost significantly more
weight (Fig. S2 and S3). Thus, by analogy with the measures of
systemic inflammation in the septic arthritis experiments, the
Table 1. Histologic joint affection after i.v. inoculation with S. aureus strain Newman, clfAPYI mutant and clfA null mutant.
Synovitis
a Cartilage/bone destruction
a
Experiment Strain No. of mice Index
b Frequency, % Index
b Frequency, %
Experiment 1 Newman 7 10.0 (7.7, 22.3) 86 6.0 (1.1, 13.7) 86
clfAPYI mutant 10 4.8 (1.3, 6.5)
c 80 1.1 (0, 3.0) 70
Experiment 2 Newman 9 15.0 (8.8, 15.6) 100 8.0 (3.5, 9.5) 100
clfAPYI mutant 10 0.6 (0, 2.7)
d 50 0 (0, 1.3)
d 50
clfA null mutant 8 2.3 (0.6, 4.2)
e 75 1.3 (0, 2.1)
f 63
aThe severity and frequency of synovitis and cartilage/bone destruction was monitored in mice 7–8 days after bacterial i.v. inoculation.
bData are median of histologic index (lower, upper quartiles).
cP=0.02 versus wild-type.
dP=0.001 versus wild-type.
eP=0.003 versus wild-type.
fP=0.006 versus WT.
doi:10.1371/journal.pone.0002206.t001
Figure 2. Bacterial growth in kidneys is hampered upon
mutation of the ClfA fibrinogen binding site. Bacterial growth
in kidneys in mice 7–8 days after inoculation with 3.2610
6–6.0610
6 cfu
of S. aureus strain Newman, and clfAPYI, clfAPYII, and clfA null mutants.
Data are represented as cfu per kidney pair. One circle represents the
kidney counts of one mouse. Where no growth was detectable, the
count was put to highest possible count according to what dilution was
used. Data from three experiments are pooled. NNewman=26, NclfAPYI
=30, NclfAPYII=10, and NclfA=15.
doi:10.1371/journal.pone.0002206.g002
Figure 3. The ClfA fibrinogen binding site affects survival after
strain Newman challenge. Survival of mice after inoculation with 5.2,
5.1 or 3.3610
7 cfu of S.aureus strain Newman, clfAPYI mutant or clfA null
mutant, respectively. N=10 per group from start.
doi:10.1371/journal.pone.0002206.g003
ClfA, Fibrinogen and Virulence
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as long as it lacks fibrinogen binding properties.
Injection of bacteria into joints
To test if the inflammatory reaction in the joint is dependent on
fibrinogen binding, Newman wild-type, Newman clfAPYI or
Newman clfA null were injected directly into a knee joint of mice,
thereby by-passing the systemic compartment. Synovitis, including
polymorphonuclear infiltration of the joint cavity, and bone
destruction was studied by histology 3 days later. The mice
received 2.4610
4 cfu of wild-type, 2.4610
4 cfu of the clfA null
mutant, or 3.4610
4 cfu of clfAPYI mutant in one knee. The
synovitis and the polymorphonuclear infiltration histologic index
in the joint cavity was 0.25 (0, 3.0) for knees infected with wild-
type, 2.38 (0.25, 3.0) for the clfA null mutant and 0.25 (0, 0.25) for
the clfAPYI mutant (median, interquartile range). The histologic
index for destruction of bone was 0 (0, 1.0) for wild-type, 1.0 (0,
1.0) for the clfA null mutant, and 0 (0, 0) for the clfAPYI mutant
(median, interquartile range; P=0.01 between the clfAPYI mutant
and the clfA null mutant). Since the clfAPYI mutant evoked very
little synovitis and destruction, despite the fact that 42% more of
that strain was given to mice than the other strains, it is concluded
that ClfA-promoted fibrinogen binding is needed for the maximal
inflammatory response within the joint. Again, the absence of ClfA
expression enhanced inflammation compared to the fibrinogen
binding deficient ClfA mutant.
PY mutation in strain LS-1
To determine if the ability of ClfA to bind fibrinogen affects
virulence of other strains of S.aureus, the clfAPYI, clfAPYII and clfA
null mutations were transduced to the TSST-1 expressing S. aureus
strain LS-1. Mice were challenged with 9.4610
6 cfu of LS-1 wild-
type, 7.9610
6 cfu of LS-1 clfAPYI , 10.7610
6 cfu of LS-1 clfAPYII,
or 9.4610
6 cfu of the LS-1 clfA null mutant. Sepsis was studied by
following the survival rate. After 16 days only 40% of mice
challenged with the wild-type strain were alive while 90% of the
mice challenged with the clfAPYI mutant and clfA null mutant
groups and 80% mice infected with the clfAPYII mutant were alive
(Fig. 4). The clfAPYI mutants and the clfA null mutant of LS-1
were significantly less virulent (P=0.014, P=0.05 and P=0.03,
respectively).
Immunization with recombinant ClfA proteins
The effect of vaccination with recombinant wild-type ClfA A
domain protein (rClfA) and mutant ClfAPYI protein (rClfAPY)
was studied in both the septic arthritis model and the sepsis model.
Mice were sensitized and then boosted twice with control protein
BSA, rClfA, or rClfAPY, and subsequently infected with 4.0610
6
cfu of S. aureus strain Newman to induce septic arthritis, or with
2.3610
7 cfu of strain Newman to induce sepsis. Immunization
with rClfAPY protected significantly against septic death as
compared to control mice (P=0.01, Fig. 5) while rClfA
immunization did not achieve significant protection. One day
before bacterial infection there was a much higher specific serum
antibody response to both rClfAPY and rClfA in mice immunized
with rClfAPY (A405=0.39 (0.33, 0.56) and 0.71 (0.52, 0.81)) as
compared to mice immunized with rClfA (A405=0.13 (0.07, 0.17)
and 0.15 (0.10, 0.24), P,0.0001 in both comparisons (median,
interquartile range)). Control immunized animals had only
background levels (A405 nm=0 and 0.01 (0, 0.01) (median,
interquartile range)). The immunized mice which were to be
infected with the lower, arthritic bacterial dose had similar
antibody responses to rClfA and rClfAPY as the mice in which
sepsis were induced (data not shown). Immunization with both
rClfA and rClfAPY protected against the development of arthritis,
although the protection was not significant (Fig. S4). During day 5
to 9 after infection the weight loss was significantly reduced in the
rClfAPY and rClfA immunized mice, as compared to the control
mice (data not shown). A trend to diminished bacterial growth in
kidneys of mice immunized with rClfAPY or rClfA at day 11 after
infection (BSA: 38 (3, 436); rClfAPY: 7 (2, 17); rClfA: 10 (7,
54)610
7 cfu/kidney pair) was observed.
Discussion
The impact of the fibrinogen binding of ClfA on the ability of S.
aureus to evoke septic arthritis and sepsis was investigated. Our data
strongly suggest that the ClfA-fibrinogen interaction is crucial for
the bacterial virulence and thus disease outcome. The ability of
ClfA to bind fibrinogen was associated with enhanced virulence in
terms of the ability to cause septic death. In both staphylococcal
strains tested, a clfAPY mutant induced less septic death than the
Figure 4. The ClfA fibrinogen binding site affects virulence of
strain LS-1. Survival of mice after inoculation with 9.4, 7.9, 10.7 or
9.8610
6 cfu of S.aureus strain LS-1, and clfAPYI, clfAPYII or clfA null
mutants, respectively. N=15 per group from start.
doi:10.1371/journal.pone.0002206.g004
Figure 5. Vaccination efficacy of ClfA is improved by mutation
of the fibrinogen binding site. Survival of mice immunized with
BSA, recombinant ClfA or recombinant ClfAPY and inoculated with
2.3610
7 cfu of S. aureus Newman. N=15 per group from start.
doi:10.1371/journal.pone.0002206.g005
ClfA, Fibrinogen and Virulence
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mice infected with the non-fibrinogen binding clfAPY mutant.
A likely mechanism for the promotion of virulence by the
fibrinogen-bacterial cell surface interaction is inhibition of
neutrophil phagocytosis. Opsonophagocytosis experiments with
human neutrophils show clearly that ClfA inhibits phagocytosis of
S. aureus, and that this in part is dependent on fibrinogen binding
because the ClfAPY mutant is only partially inhibiting [5].
Neutrophils are crucial for the host defence in the early phase of S.
aureus infection [13]. Without neutrophils, bacterial growth is
strongly augmented in blood and kidneys, and the frequency of
arthritis and mortality increases. Fibrinogen mediated inhibition of
neutrophil phagocytosis by ClfA could explain at least in part
the more pronounced virulence of wildtype S. aureus compared to
the clfAPY mutants. Binding of fibrinogen to ClfA could decrease
opsonophagocytosis by neutrophils by reducing opsonin deposition
or access to opsonins by neutrophil receptors. ClfA could
also specifically block phagocytosis, for example by interfering
with the fibrinogen binding phagocyte integrin Mac-1. The
streptococcal M5 protein has been shown to block phagocytosis
by neutrophils by interfering with Mac-1 [14], and the fibrinogen
binding region of the M5 protein is essential for resistance to
phagocytosis [15]. Alternatively, bound fibrinogen might block the
binding of an unknown protective host factor to S. aureus. Another
option is that the fibrinogen-ClfA interaction promotes bacterial
passage from blood vessel into the tissue or promotes colonization
in tissues.
Unexpectedly, our data also show the ClfA null mutant was
more virulent than the clfAPY mutant strains. Possibly the ClfA
protein has functions in vivo other than interacting with
fibrinogen. This interaction is clearly disadvantageous for the host
as shown in this study. Other functions of ClfA are presently not
well mapped but non-fibrinogen dependent platelet aggregation
exerted by ClfA might result in trapping of big amounts of S. aureus
in circulation with subsequent elimination of the bacterial–platelet
complexes through the reticuloendothelial system. Such platelet
aggregation mediated elimination of staphylococci would readily
occur in the wild-type and clfAPY mutated strains but not in the
clfA knockout. Whereas in the wild-type strain the fibrinogen
interaction would overshadow the other events, in the clfAPY
mutants such bacterial eliminiation might be highly beneficial to
the host.
The clfA knockout mutant protected against septic death to the
same degree as the clfAPY mutation in S. aureus strain LS-1, but
protected less, if at all, in strain Newman. The overall impact of
ClfA expression on bacterial virulence could differ between
different S. aureus strains depending on the level of expression
and the presence of other virulence factors.
The issue whether the clfAPY mutant displays equal or lower
virulence once in the joint cavity is of certain importance having in
mind that in inflamed synovial fluid fibrinogen and fibrin are
abundant. Our data suggest that the clfAPY mutant is less
destructive for cartilage and bone.
The protective effect of recombinant ClfA A domain non-
fibrinogen binding P336Y338 mutant was greater than for wild-type
rClfA. Immunization with ClfAPY enhanced the serum levels of
specific antibodies that recognized both the immunogen and the
wild-type ClfA protein. More importantly, it induced a greater
protective immune response against septic death than wild-type
ClfA. In contrast, we did not see a similar significant correlation in
case of septic arthritis. We interpret the differences between the
two infection models to accessibility of antibodies to different body
compartments which is excellent in the blood stream (sepsis) and
lower in the joint cavity during septic arthritis.
We hypothesize that binding of fibrinogen by wild-type ClfA
protein during the immunization phase decreases antigen
presentation due to hiding of important epitopes on the ClfA
molecule and hence decreases specific antibody production. This
finding implies that PY mutant ClfA might be a considerably
better vaccine candidate than wild type recombinant ClfA.
Materials and Methods
Mice
NMRI mice were obtained from Scanbur BK (Sollentuna,
Sweden) and were maintained in the animal facility of the
Department of Rheumatology, University of Go ¨teborg, Sweden.
Go ¨teborg animal experiment ethic board approved the experi-
ments, and all experiments conform to the animal husbandry
standards of this ethic board. The mice were housed up to 10
animals per cage with a 12 h light-dark cycle, and were fed
standard laboratory chow and water ad libitum. The animals were
6 to 16 weeks old at the start of the experiments.
Bacterial strains
For infection of animals the S. aureus wildtype strains Newman
[16] and LS-1 [11] and constructed derivatives thereof were used.
The clfA P336SY338A( clfAPYI) and clfA P336AY338S( clfAPYII)
derivatives were constructed in strain Newman and transduced to
strain LS-1 (see below). The deletion mutants Newman
clfA2::Tn917 mutant DU5876 [3] and LS-1 clfA2::Tn917 mutant
(J.R. Fitzgerald et al., unpublished) were also used. Bacteria were
grown on blood agar plates for 48 h, harvested, and kept frozen at
220uC in PBS containing 5% (wt/vol) BSA (Sigma Chemicals)
and 10% (vol/vol) dimethyl sulfoxide. Before injection into
animals, the bacterial suspensions were thawed, washed in PBS,
and adjusted to appropriate cell concentrations. The number of
viable bacteria was measured in conjunction with each challenge
by cultivation on blood agar plates and counting colonies.
Construction of clfAPYI and clfAPYII mutations in S.
aureus Newman and LS-1
A 1.02 kb PstI-BamHI fragment of pCF77 PY [6] containing the
mutations P336S and Y338Ai nclfA was cloned into pBluescriptII
SK- (Stratagene). This plasmid was linearised with HindIII and
ligated to HindIII-cut pTSermC (J. Higgins et al., unpublished) to
generate plasmid pARM, which is a temperature sensitive E. coli-S.
aureus shuttle vector containing the P336S and Y338A substitutions.
In order to reduce the risk of unknowingly generating a
functional or immunoreactive epitope by substituting P336 and
Y338, we generated a second mutant, in which the order of the
substitutions was reversed, yielding P336A and Y338S. To generate
this a plasmid pJH2, analogous to pARM but containing the P336A
and Y338S subsitutions, was generated. Overlap primer PCR was
used with the same flanking primers used to make pCF77 PY [6],
and a different pair of overlapping mutagenic primers: F3:
GCAACTTTGACCATGGCCGCTTCTATTGACCCTGAAAATG
and R3: CATTTTCAGGGTCAATAGAAGCGGCCATGGT-
CAAAGTTGC (mutations in bold and underlined) to generate
pCF77 PYII. The 1.02 kb PstI-HindIII fragment of this plasmid
was used as described above to generate pJH2, a temperature
sensitive E. coli-S. aureus shuttle vector containing the P336A and
Y338S substitutions.
Both pARM and pJH2 were transferred to RN4220 [17] by
electroporation and subsequently transduced using phage 85 [18]
to S. aureus Newman [16] and LS-1 [11]. In these strains the
plasmids were induced to insert into the chromosome and then
excise, leaving the mutations in the chromosome of a proportion of
ClfA, Fibrinogen and Virulence
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LS-1 clfAPYI and LS-1 clfAPYII. Transformants were screened for
loss of the plasmid and a loss of fibrinogen-binding activity.
Integrity of the clfA gene was verified by Southern hybridisation
using a clfA probe (data not shown). Expression of an immuno-
reactive protein (ClfAPY) was verified by Western immunoblotting
using anti-ClfA region A polyclonal rabbit antiserum (data not
shown). The mutations were verified by PCR across the KpnI-
BamHI fragments from genomic DNA and commercial sequencing
of the products. The about 700 bases of the clfA gene of strain LS-1
that were sequenced were identical to the corresponding bases in
the Newman clfA gene of strain Newman.
Recombinant ClfA and ClfAPY
His-tagged recombinant ClfA region A, domains N123
(amino acids 40–559), was produced from pCF40 as pre-
viously described [19], with an additional polishing step through
an anion-exchange column. Plasmid pCF77 PY [6] was used
as template to clone clfAPYI domains N123 into pQE30 to
generate pCF40PY. Using this plasmid, recombinant ClfAPY was
also produced by nickel affinity chromatography and anion
exchange chromatograpy, as was described for rClfA. Eluates
were dialysed against two changes of PBS before concentration
and freeze-drying.
Septic arthritis and sepsis experiments
In experiments 1–3 all the mice (n=10 per group) were infected
with strain Newman to trigger arthritis. In experiments 4 and 5,
the mice were infected with strain Newman and LS-1, respectively,
to induce sepsis (n=10 per group).
Experiment 1. Mice were infected by intravenous injection
with 3.5610
6 cfu/mouse of S.aureus strain Newman or with
4.3610
6 cfu/mouse of Newman clfAPYI mutant, both in 200 ml
PBS. Clinical arthritis and weight change was followed until day 7.
Mice were sacrificed day 8, kidney growth of bacteria were
assessed and serum IL-6 and total IgG levels were measured.
Synovitis and bone destruction was studied histologically on the
joints of fore and hind legs.
Experiment 2. Mice were infected with 5.0610
6 cfu,
6.0610
6 cfu or 4.3610
6 cfu of S.aureus strain Newman, clfAPYI
mutant or Newman clfA::Erm
R (clfA null mutant), respectively.
Clinical arthritis and weight change was followed until day 7. Mice
were sacrificed day 7, kidney growth of bacteria were assessed and
serum IL-6 and total IgG levels were measured. Synovitis and
bone destruction was studied histologically on the joints of fore and
hind legs.
Experiment 3. Mice were infected with 4.7610
6 cfu,
3.2610
6 cfu, 3.9610
6 cfu or 4.8610
6 cfu of S.aureus strain
Newman, clfAPYI mutant, Newman clfAPYII mutant or Newman
clfA null mutant, respectively. Clinical arthritis and weight change
was followed until day 7. Mice were sacrificed day 8 and kidney
growth of bacteria were assessed.
The outcome of the experiments 1–3 were very similar, so data
were pooled and presented together.
In experiment 4 mice were injected intravenously with 5.2610
7
cfu, 5.1610
7 cfu or 3.3610
7 cfu of S.aureus strain Newman, clfAPYI
mutant or clfA null mutant, respectively. Mortality, weight change
and clinical arthritis were followed until day 10.
In experiment 5 mice were infected with 9.4610
6 cfu, 7.9610
6
cfu, 10.7610
6 cfu or 9.8610
6 cfu of S.aureus strain LS-1, LS-1
clfAPYI mutant, LS-1 clfAPYII mutant, or LS-1 clfA null mutant,
respectively. Mortality, clinical arthritis and weight change was
followed until day 16.
Intra-articular injection of bacteria
One knee joint per mouse was injected with 2.4610
4 cfu,
2.4610
4 cfu, or 3.4610
4 cfu of strain Newman wildtype, clfAPYI
mutant or clfA knockout mutant, respectively, in 20 ml PBS. N=10
per group. Mice were sacrificed 3 days later, and the knee joints
were collected for histopathological examination.
Vaccination with wild-type and mutant recombinant ClfA
Purified rClfA, rClfAPY or BSA were dissolved in physiologic
saline and emulsified 1:1 in Freunds complete adjuvant (Difco
Laboratories). Two hundred ml of the emulsion containing 30 mg
of protein was injected subcutaneously (s.c.) on day 0. First booster
immunization with 30 mg of protein in physiologic saline in
incomplete Freunds adjuvant was performed on day 11. Second
booster immunization was done day 21.
On day 31, 14–15 mice per group were infected by i.v. injection
of 4.0610
6 cfu/mouse for induction of septic arthritis, or by
2.3610
7 cfu/mouse for induction of sepsis. Clinical arthritis,
weight change and mortality were followed for 11 and 15 days,
respectively. Bacterial growth in kidneys was assessed in the septic
arthritis experiment.
Clinical evaluation of infected mice
The clinical evaluation was performed in a blinded manner.
Each limb was inspected visually. The inspection yielded a score of
0 to 3 (0, no swelling and erythema; 1, mild swelling and/or
erythema; 2, moderate swelling and/or erythema; 3 marked
swelling and/or erythema). The arthritic index of an animal was
constructed by adding the scores from all four limbs. The
presented arthritic index is thus the severity of arthritis, measured
as the sum of scores, of all mice in a group. The overall condition
of each mouse was also examined by assessing signs of systemic
inflammation, i.e., weight decrease, reduced alertness, and ruffled
coat. In cases of severe systemic infection, when a mouse was
judged too ill to survive another 24 h, it was killed by cervical
dislocation and considered dead due to sepsis.
Histological examination
Histological examination of joints was performed using a
modification [8] of a previously described method [20]. Briefly,
microscopic inspection yielded a score for each joint for severity of
synovitis and cartilage/bone destruction. Synovitis was scored as
0–3 and cartilage and/or bone destruction was scored as 0–2.
Totally 12 joints per animal were examined. The histologic index,
for severity of synovitis and cartilage/bone destruction respective-
ly, was calculated by adding the scores for the 12 joints of an
animal.
Bacteriologic examination of infected kidneys
Kidneys were aseptically dissected, kept on ice, homogenised,
serially diluted in PBS and spread on blood agar plates. After 24 h
of incubation in 37uC the number of cfu per kidney pair was
determined.
Measurement of serum IgG
Levels in serum of total IgG were measured by the radial
immunodiffusion technique [21]. Goat-Anti-Mouse-IgG and
mouse IgG standard were purchased from Southern Biotech,
Birmingham, AL.
Specific antibodies
Serum samples from immunized mice were obtained 9 days
after the second booster immunization. The serum levels of
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ELISA. Microplates (96-well; Nunc) were coated with 5 mg/ml of
recombinant protein in PBS. Blocking agent, serum samples,
biotinylated antibodies, and ExtrAvidin-proxidase were all diluted
in PBS. The assay was run according to a previous description [8].
All serum samples were diluted 1:20000, and antibody response
was monitored as absorbance at 405 nm.
IL-6 analysis
Serum IL-6 was detected by a method previously described
[22].
Statistical analysis
Statistical evaluation was done by using the Mann-Whitney U
test when comparing two groups, the Kruskal-Wallis test with a
following post-hoc analysis when there were three or more groups
to compare, or the Kaplan-Meier analysis with a Tarone-Ware
test at survival analysis. The Chi-square test was used for
frequency comparisons. P,0.05 was considered to be significant.
No correction for multiple comparisons was employed. Data are
reported as medians, interquartile ranges, and 80% central ranges,
unless otherwise mentioned.
Supporting Information
Figure S1 The fibrinogen binding site of ClfA mediates
enhanced frequency of septic arthritis. Frequency of arthritic mice
inoculated with 3.2610
6–6.0610
6 cfu of S. aureus strain Newman
wild-type, and clfAPYI, clfAPYII, and clfA null mutants. Data from
three experiments are pooled. NNewman=27–30, NclfAPYI=30,
NclfAPYII=10, and NclfA null=16–20.
Found at: doi:10.1371/journal.pone.0002206.s001 (1.23 MB TIF)
Figure S2 Severity of arthritis in septic mice is ameliorated upon
fibrinogen binding site mutation. Severity of arthritis measured as
arthritic index in mice inoculated with 5.2, 5.1 or 3.36107 cfu of
S.aureus strain Newman wild-type, clfAPYI mutant or clfA null
mutant, respectively. Data are presented as medians (squares),
interquartile ranges (boxes), and 80% central ranges (whiskers).
NNewman=0–10, NclfAPYI=9–10, and NclfA null=1–10. All Newman
wild-type infected mice were dead by day 5.
Found at: doi:10.1371/journal.pone.0002206.s002 (0.42 MB TIF)
Figure S3 Weight loss in septic mice is less pronounced upon
fibrinogen binding site mutation. Weight loss in mice inoculated
with 5.2, 5.1 or 3.3610
7 cfu of S.aureus strain Newman wild-type,
clfAPYI mutant or clfA null mutant, respectively. Data are
presented as medians (center line), interquartile ranges (boxes),
and 80% central ranges (whiskers). NNewman=0–10, NclfAPYI=9–
10, and NclfA null=1–10. All Newman wild-type infected mice were
dead by day 5.
Found at: doi:10.1371/journal.pone.0002206.s003 (0.42 MB TIF)
Figure S4 Vaccination efficacy of ClfA on septic arthritis with
and without mutation of the fibrinogen binding site. Severity of
arthritis measured as arthritic index in mice immunized with BSA,
recombinant ClfA or recombinant ClfAPY and inoculated with
4.0610
6 cfu of S. aureus Newman. Data are presented as medians
(squares), interquartile ranges (boxes), and 80% central ranges
(whiskers). NBSA=14, NrclfAPY=14, and NrclfA=15 per group from
start.
Found at: doi:10.1371/journal.pone.0002206.s004 (0.42 MB TIF)
Acknowledgments
We gratefully acknowledge valuable contributions from Alistair R. Macey,
who made a plasmid, Ing-Marie Jonsson, for tissue and bacteria sampling,
Berit Jarlstedt, for preparation of histological samples, and Margareta
Verdrengh for running serological assays.
Author Contributions
Conceived and designed the experiments: TF AT EJ. Performed the
experiments: EJ JH. Analyzed the data: TF AT EJ JH. Contributed
reagents/materials/analysis tools: TF AT EJ JH. Wrote the paper: TF AT
EJ JH.
References
1. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, et al. (2002) Virulent
combinations of adhesin and toxin genes in natural populations of Staphylococcus
aureus. Infect Immun 70: 4987–4996.
2. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, et al. (1997)
Characterization of the interaction between the Staphylococcus aureus clumping
factor (ClfA) and fibrinogen. Eur J Biochem 247: 416–424.
3. McDevitt D, Francois P, Vaudaux P, Foster TJ (1994) Molecular characteriza-
tion of the clumping factor (fibrinogen receptor) of Staphylococcus aureus.M o l
Microbiol 11: 237–248.
4. Palmqvist N, Patti JM, Tarkowski A, Josefsson E (2004) Expression of
staphylococcal clumping factor A impedes macrophage phagocytosis. Microb
Infect 6: 188–195.
5. Higgins J, Loughman A, van Kessel KPM, van Strijp JAG, Foster TJ (2006)
Clumping factor A of Staphylococcus aureus inhibits phagocytosis by human
polymorphonuclear leucocytes. FEMS Micriobiol Lett 258: 290–296.
6. Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, et al. (2005)
Roles of fibrinogen, immunoglobulin and complement in platelet activation
promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 57: 804–818.
7. O’Brien L, Kerrigan SW, Kaw G, Hogan M, Penade ´s J, et al. (2002) Multiple
mechanisms for the activation of human platelet aggregation by Staphylococcus
aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat
protein SdrE and protein A. Mol Microbiol 44: 1033–1044.
8. Josefsson E, Hartford O, O’Brien L, Patti JM, Foster T (2001) Protection against
experimental Staphylococcus aureus arthritis by vaccination with clumping factor A,
a novel virulence determinant. J Infect Dis 184: 1572–1580.
9. Palmqvist N, Foster T, Fitzgerald R, Josefsson E, Tarkowski A (2005)
Fibronectin-binding proteins and fibrinogen-binding clumping factors play
distinct roles in staphylococcal arthritis and systemic inflammation. J Inf Dis 191:
791–798.
10. Deivanayagam CCS, Wann ER, Chen W, Carson M, Rajashankar KR, et al.
(2002) A novel variant of the immunoglobulin fold in surface adhesins of
Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM,
clumping factor A. The EMBO Journal 21: 6660–6672.
11. Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A (1991) Experimental
Staphylococcus aureus arthritis in mice. Infect Immun 59: 2615–2623.
12. Sakiniene E, Bremell T, Tarkowski A (1996) Addition of corticosteroids to
antibiotic treatment ameliorates the course of experimental Staphylococcus aureus
arthritis. Arthritis Rheum 39: 1596–1605.
13. Verdrengh M, Tarkowski A (1997) Role of neutrophils in experimental
septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun
65: 2517–2521.
14. Weineisen M, Sjo ¨bring U, Fa ¨llman M, Andersson T (2004) Streptococcal M5
protein prevents neutrophil phagocytosis by interfering with CD11b/CD18
receptor-mediated association and signaling. J Immunol 172: 3798–3807.
15. Sandin C, Carlsson F, Lindahl G (2006) Binding of human plasma proteins to
Streptococcus pyogenes M protein determines the location of opsonic and non-
opsonic epitopes. Mol Microbiol 59: 20–30.
16. Duthie ES, Lorenz LL (1952) Staphylococcal coagulase: mode of action and
antigenicity. J Gen Microbiol 6: 95–107.
17. Kreiswirth BN, Lo ¨fdahl S, Betley MJ, O’Reilly M, Schlievert PM, et al. (1983)
The toxic shock syndrome exotoxin structural gene is not detectably transmitted
by a prophage. Nature 305: 709–712.
18. Foster TJ (1998) Molecular genetic analysis of staphylococcal virulence. In:
Williams P, Ketley J, Salmond G, eds. Methods in Microbiology Vol 27:
Bacterial Pathogenesis. London: Academic Press. pp 433–454.
19. O’Connell DP, Nanavaty T, McDevitt D, Gurusiddappa S, Ho ¨o ¨k M, et al.
(1998) The fibrinogen-binding MSCRAMM (clumping factor) of Staphylococcus
aureus has a Ca
2++-dependent inhibitory site. J Biol Chem 273: 6821–6829.
20. Sakiniene E, Bremell T, Tarkowski A (1999) Complement depletion aggravates
Staphylococcus aureus septicaemia and septic arthritis. Clin Exp Immunol 115:
95–102.
21. Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation
of antigens by single radial immunodiffusion. Immunochemistry 2: 235–254.
22. Bremell T, Abdelnour A, Tarkowski A (1992) Histopathological and serological
progression of experimental Staphylococcus aureus arthritis. Infect Immun 60:
2976–2985.
ClfA, Fibrinogen and Virulence
PLoS ONE | www.plosone.org 7 May 2008 | Volume 3 | Issue 5 | e2206